Ark Biotech is a company.
Ark Biotech has raised $3.0M across 1 funding round.
Key people at Ark Biotech.
Ark Biotech has raised $3.0M in total across 1 funding round.
Key people at Ark Biotech.
Ark Biotech is a biotech startup developing a high-fidelity bioprocess simulation platform and intelligent bioreactors to accelerate molecule development from lab to market.[1][2][4] It serves biopharma companies, CDMOs, and biotech startups by replacing slow, expensive trial-and-error experiments with AI-driven hybrid models that predict outcomes, optimize processes, and enable precise scaling—reducing R&D timelines, costs, and barriers to life-saving therapies like cell and fermentation products, including cultivated meat.[1][2][3][4] The platform analyzes 25+ cell culture trends (e.g., titer, viability, lactate), runs virtual experiments in seconds, performs in silico optimizations across thousands of variations, and supports scale-up from pre-IND to commercial production with no coding required.[4]
Growth momentum stems from trust by top biopharma and CDMOs for manufacturing improvements, residency at The Engine (MIT's tough tech accelerator), and backing from Siddhi Capital, positioning it to address escalating bioprocessing costs and timelines.[2][3][4]
Ark Biotech was founded by Zheng Huang and Yossi Quint, who combined their expertise to tackle bioprocessing inefficiencies.[1] Zheng, with over a decade in biopharmaceuticals including Director of MSAT at Sanofi (leading tech transfer, process modeling, and automation), identified the need for data-driven approaches.[1] Yossi, a former quantitative researcher in finance, saw predictive modeling's potential to transform industries.[1] Their shared vision emerged from these experiences: harnessing biology, chemistry, physics, machine learning, and AI via hybrid models to speed innovation.[1]
Early traction includes building a comprehensive simulation platform and intelligent bioreactor, with residency at The Engine and investment from Siddhi Capital under food tech themes like cultivated meat production.[2][3] Advisors like Ariel Katz (H1 CEO), Prof. Abba M. Krieger (Wharton), and Robert Kiss (ex-Genentech) bolster credibility.[1]
Ark Biotech rides the AI-for-science wave in biotech, where predictive modeling disrupts traditional wet-lab bottlenecks amid rising costs and timelines for cell/gene therapies, cultivated meat, and fermentation products.[1][2][3] Timing aligns with surging demand for scalable bioprocessing—pharma/biotechs face years of error-prone experiments, but Ark's platform cuts R&D by enabling rapid, precise predictions and optimizations.[2][4]
Market forces favor it: AI adoption in drug development (e.g., hybrid models), precision fermentation growth for alt-proteins, and bioreactor innovations for industrial-scale cultivated meat without animals.[3] It influences the ecosystem by democratizing access—making breakthroughs affordable/faster for startups and incumbents, accelerating therapies to patients, and supporting sustainability via animal-free proteins.[1][2][3]
Ark Biotech is poised to dominate bioprocess digital twins, expanding from simulations to fully autonomous intelligent bioreactors integrated with real-time optimization.[2][4] Trends like multimodal AI, edge computing in bioreactors, and regulatory embrace of in silico data (e.g., FDA pilots) will propel growth, especially in cultivated meat's $25B+ market and cell therapy scaling.[3] Influence may evolve via partnerships with big pharma and platform-as-a-service models, potentially acquiring wet-lab validation tools.
This positions Ark as a linchpin in biotech's lab-to-market acceleration, fulfilling its founding promise of innovation at the speed of possibility.[1]
Ark Biotech has raised $3.0M in total across 1 funding round.
Ark Biotech's investors include 14W, 20VC, Adjacent, Astanor Ventures, First Round Capital, Founders Fund, Greylock, Hardware Club, January Ventures, Night Capital, UP.Partners, Alexandre Scialom.
Ark Biotech has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2021 | $3.0M Seed | 14W, 20VC, Adjacent, Astanor Ventures, First Round Capital, Founders Fund, Greylock, Hardware Club, January Ventures, Night Capital, UP.Partners, Alexandre Scialom, Bradley Horowitz, Casey Neistat, James Beshara, Jean Charles Samuelian, Jeffrey Wilke, Steve Schlafman, Thibaud Elziere |
